Topical antibacterial therapy of the eye is limited less by the intrinsic potency of the drug than by the speed with which the eye rejects it. A conventional drop is diluted by the tear film, spread over the ocular surface, and drained through the nasolacrimal duct within a few minutes, so that only a small fraction of the instilled dose ever reaches the corneal tissue. In-situ gelling systems address this loss directly: a low-viscosity liquid is instilled as an ordinary drop and undergoes a sol-to-gel transition on the ocular surface in response to temperature, ionic strength or pH, forming a retained depot that resists drainage. This work assembles the formulation, rheological and antibacterial evidence for ciprofloxacin in-situ ophthalmic gels and adds two computational analyses of the drug itself. Ciprofloxacin was profiled in silico for its physicochemical and drug-likeness properties, and its precorneal disposition was simulated with an apparent first-order elimination model to compare a conventional solution against an in-situ gel. Ciprofloxacin was calculated to have a molecular weight of 331.35 g/mol, a calculated logP of 1.58, a topological polar surface area of 74.6 square angstroms, and full compliance with the Lipinski, Veber, Egan and Ghose rule sets, with a quantitative drug-likeness estimate of 0.89. In the precorneal simulation, extending the apparent precorneal half-life from 2.5 to 15 min raised the mean residence time from 3.6 to 21.6 min and the precorneal exposure six-fold, and it lengthened the time for which the surface concentration remained above the ciprofloxacin minimum inhibitory concentration for Pseudomonas aeruginosa from about 26 min to about 158 min. The results, read together with the published formulation and antibacterial data, support the pharmacokinetic rationale for an in-situ gelling ciprofloxacin system while making plain the boundary between what was computed and what has been measured at the bench.